Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 29;23(13):7203.
doi: 10.3390/ijms23137203.

Human Gammaherpesvirus 8 Oncogenes Associated with Kaposi's Sarcoma

Amanda de Oliveira Lopes  1 , Pedro do Nascimento Marinho  1 , Letícia d'Ambrosio de Souza Medeiros  1 , Vanessa Salete de Paula  1
Affiliations
Review

Human Gammaherpesvirus 8 Oncogenes Associated with Kaposi's Sarcoma

Amanda de Oliveira Lopes et al. Int J Mol Sci. .

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human gammaherpesvirus 8 (HHV-8), contains oncogenes and proteins that modulate various cellular functions, including proliferation, differentiation, survival, and apoptosis, and is integral to KSHV infection and oncogenicity. In this review, we describe the most important KSHV genes [ORF 73 (LANA), ORF 72 (vCyclin), ORF 71 or ORFK13 (vFLIP), ORF 74 (vGPCR), ORF 16 (vBcl-2), ORF K2 (vIL-6), ORF K9 (vIRF 1)/ORF K10.5, ORF K10.6 (vIRF 3), ORF K1 (K1), ORF K15 (K15), and ORF 36 (vPK)] that have the potential to induce malignant phenotypic characteristics of Kaposi's sarcoma. These oncogenes can be explored in prospective studies as future therapeutic targets of Kaposi's sarcoma.

Keywords: Kaposi’s sarcoma; Kaposi’s sarcoma associated herpesvirus; oncogenes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Therapeutics targets in signaling pathways modulated by Kaposi sarcoma-associated virus (KSHV) oncoproteins. The pathways shown include PI3K/Akt/mTOR associated with vGPCR (lytic oncoprotein), NF-kB associated with vFLIP (latency oncoprotein), and different pathways associated with LANA (latency oncoprotein). A total of 5 therapies are represented outside the cell and their respective targets are indicated with the letter “X” in red color.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. de Oliveira Lopes A., Spitz N., Martinelli K.G., de Paula A.V., de Castro Conde Toscano A.L., Braz-Silva P.H., Dos Santos Barbosa Netto J., Tozetto-Mendoza T.R., de Paula V.S. Introduction of human gammaherpesvirus 8 genotypes A, B, and C into Brazil from multiple geographic regions. Virus Res. 2020;276:197828. doi: 10.1016/j.virusres.2019.197828. - DOI - PubMed
    1. Cancer Today. [(accessed on 16 December 2021)]. Available online: https://gco.iarc.fr/today/home.
    1. Pérez C.L., Tous M.I. Diversity of human herpesvirus 8 genotypes in patients with AIDS and non-AIDS associated Kaposi’s sarcoma, Castleman’s disease and primary effusion lymphoma in Argentina. J. Med. Virol. 2017;89:2020–2028. doi: 10.1002/jmv.24876. - DOI - PubMed
    1. Dalla Pria A., Pinato D.J., Bracchi M., Bower M. Recent advances in HIV-associated Kaposi sarcoma. F1000Research. 2019;8:1–9. doi: 10.12688/f1000research.17401.1. - DOI - PMC - PubMed
    1. Uppal T., Banerjee S., Sun Z., Verma S.C., Robertson E.S. KSHV LANA—The master regulator of KSHV latency. Viruses. 2014;6:4961–4998. doi: 10.3390/v6124961. - DOI - PMC - PubMed

Grants and funding

This research was funded by the National Council of Scientific and Technological Development (CNPq), Coordination for the Improvement of Higher Education Personnel (CAPES), State of Rio de Janeiro Research Support Foundation (FAPERJ), and INOVA FIOCRUZ.